But she adds that not all hope is lost. “It really is the neurology, as well as the muscular system and the interactions between the two, that changes,” she says. “And there’s a fair ...

The news: Myosana Therapeutics, a Seattle startup developing gene therapy technology, raised $5 million to develop an early-stage candidate treatment for Duchenne muscular dystrophy (DMD).

Duchenne muscular dystrophy (DMD) is a muscle degeneration disorder caused by mutations affecting the dystrophin gene. Researchers show how a dual CRISPR RNA method restored dystrophin protein ...